|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Low
dose gossypol for male contraception
Zhi-Ping
GU1, Bai-Yong MAO1, Yi-Xin WANG2, Ren-An
ZHANG3, Yong-Zhi TAN4,
Zheng-Xing CHEN2, Lin CAO1, Gen-Di YOU1,
S.J. Segal5 1Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai
200031, China Asian J Androl 2000 Dec; 2: 283-287 Keywords:
AbstractAim: To ascertain whether the side effects of gossypol, hypokalemia and irreversibility, could be avoided on dose reduction. Methods: Seventy-seven male volunteers were divided into 3 groups: control (22 cases), 10 mg gossypol (29 cases) and 12.5 mg (26 cases). Serum levels of testosterone, FSH and LH were measured by RIA and potassium by flame photometry. Sperm counts and motility were examined before and regularly after treatment for the evaluation of contraceptive efficacy. Results: The average sperm density and motility started to decrease significantly by the end of month 2 of medication and gradually reached the infertility levels (<4 million /mL) in both treated groups. After that the 10 mg group was asked to take the same dose every other day for up to a total observation period of 16-18 months for the maintenance of infertility. Subjects in the 12.5 mg group did not take gossypol any more so as to observe the length of the loading dose required, but in a few, a maintenance dose of 12.5 mg every other day was instituted for a few more months. In both treated groups, none of the spouses was pregnant during the maintenance dose period. Serum levels of potassium, FSH, LH and testosterone were not significantly changed and not a single volunteer complained of myoasthenia. After cessation of drug administratioin, the semen data returned to pretreatment levels. Conclusion: A regimen with 10 or 12.5 mg of gossypol as the daily loading dose and 35 or 43.75 mg as the weekly maintenance dose could induce infertility in male volunteers without developing hypokalemia or irreversibility.1 IntroductionGossypol, a yellow polyphenolic compound isolated from the seed of the cotton plant (family Malvaceae), has been reported to induce infertility by suppressing spermatogenesis[1]. In a multicentre study carried out in China, 8086 male volunteers from 14 provinces, were treated with gossypol for contraceptive purposes. Results showed that the effective rate of contraception was 98.5% at anoral dose of 20 mg per day for 75 days as the initial dose, followed by a maintenance dose of 40-50 mg per week[2]. Gossypol was thus considered by some as a potential male contraceptive[3]. However, hypokalemia and irreversibility, side effects occurring in a few subjects, caused hesitations and doubts for its clinical use. The average incidence of hypokalemia was found to be 0.75% and that of irreversibility, 9.90%[2]. So far, preventive measures for these side effects have not been available in the literature. The present study was an attempt to explore an optimal dose that might induce contraception without developing hypokalemia and irreversibility.2 Materials and methods2.1
Treatment Seventy-seven
male volunteers with normal fertility and renal function were divided
into 3 groups: (1) Control: 22 cases, (2) 10 mg group: 29 cases, and (3)
12.5 mg group: 26 cases. In the treatment groups, subjects were given
gossypol at a daily oral dose of 10 or 12.5 mg until their sperm counts
decreased to the generally accepted infertile level (<4 million/mL).
After that volunteers in the 10 mg group were asked to take the same dose
every other day to see whether the dose regime could maintain the contraceptive
efficacy, up to a total observation period of 16-18 months. Subjects in
the 12.5 mg group did not take gossypol any more as the purpose of this
group was to observe the length of the loading dose required, but a number
of subjects were advised to take a maintenance dose of 12.5 mg every other
day for a few more months. All the subjects were asked to follow the dose
regime strictly. During the trial, condoms, but no other contraceptive
measures, were used until the sperm counts reached the infertile level to
avoid unwanted pregnancy. For the controls, condoms were used during the
whole observation period. 2.2
Semen examination Sperm
counts and motility were measured before medication, and
monthly after the commencement of medication. Semen specimens were
obtained after 2-4 days of sexual abstinence. 2.3
Serum potassium and hormones Blood
samples were collected between
08:00 and
10:00 on the day
before medication
and at monthly intervals after the commencement of treatment. Serum levels
of testosterone, FSH and LH were measured by RIA and potassium by flame
photometry. 2.4
Statistical analysis 3 Results 3.1
Spouse pregnancy None
of the spouses of the two treatment groups conceived during the period
of maintenance dose, when condom was no longer used. 3.2
Duration of gossypol administration (Table 1)
In
the 10 mg group, 8 cases stopped medication by the end of month 9 and
18 cases, by the end of
month 12. In the 12.5 mg group 11 subjects stopped to take
gossypol by the end of month
8 and 15 cases continued to take the maintenance dose for two more
months and 4 cases for 4 more months. Table
1. Duration
of gossypol administration (No. of cases).
3.3
Length of the loading phase Table
2 shows the distribution of subjects by length of the loading phase. At
the end of 6 month medication, in 69% of subjects in the 10 mg group and
73% of subjects in the 12.5 mg group, semen data reached the infertile
levels. In the 12.5 mg group, the sperm count in one case decreased to
less than 4 million/mL by the end of month 2
and in 9 cases, by the end of month 3 of treatment. By the
end of month 4, the semen data of 12 cases in the 12.5 mg group and 13
case in the 10 mg
group reached infertile level; these values were not significantly different. Table
2. Distribution
of subjects according to the duration of the loading phase.
3.4
Semen examination As
shown in Tables 3 and 4, in both treated groups the average sperm density
and motility started to decrease significantly by the end of month 2 of
medication and gradually
reached infertile levels. Figures
1 and 2 show the pharmacodynamic
profiles of sperm density and percentage of the mobile sperm in both groups. Table
3. Sperm density,
motility and serum potas 10
mg gossypol group
means (n). bP<0.05, cP<0.01,
as compared with the control or admission level.
Table
4. Sperm
density, motility and serum potassium
in 12.5 mg gossypol group means (n). bP<0.05,
cP<0.01,as compared with the admission level.
Figure
1.
Average Sperm density (meanSD) of subjects in control and treated
groups. 3.5
Hormone profiles Table 5 shows serum levels of FSH, LH and testosterone in the 10 mg group. They were not significantly different from the levels at admission. Table
5. Serum concentration of LH, FSH and testostero
in 10 mg gossypol medication means (n).
3.6
Serum potassium The
serum potassium levels of subjects in treated groups are presented in
Table 3 and 4. In the 12.5 mg group (Table 6), the serum K levels in 7
cases were occassionally lower than 3.5 mEq/L during the whole observation
period. However, it would spontaneously return to the normal level during
the next follow up even when the subject continued to take gossypol. None
of them complained of hypokalemic myoasthenia.
Figure 3 shows the profile of blood K+ during the whole
year in the 10 mg group and control group. Lower serum K+ was
seen in the summer season
both in the control and treated groups. The K+ values in control
subjects in August of 1987 and 1988 was 3.900.25 and 3.900.22 mEq/L
respectively, while
in treated group they were 3.860.30 and 3.750.28 mEq/L respectively.
There were no significant differences between the data of the two groups.
Table
6. Subjects in whom serum potassium levels appeared below 3.5 mEq/L in
12.5 mg group.
Figure
3. The profile of blood
potassium during a year in 10 mg group and control. 4 Discussion Results
of the present study indicated that the low dose gossypol regimen (10
or 12.5 mg) could induce infertility in the majority of subjects. The
requirement for a longer loading phase, however, was the principal disadvantage
of this regimen. No demonstrable alterations were found in the hormone
profiles. Our previous study provided evidence that FSH might be the only
hormone stepping up significantly at the early stage of the maintenance
phase in subjects exhibiting irreversibility and hence, we concluded that
monitoring of serum FSH levels could be used as a diagnostic tool
for identifying these kind of subjects during gossypol treatment[4].
In the present low dose trial, normal FSH levels during medication might
indicate that there would not be much risk for the development of irreversibility. References [1]
National Coordinating Group on Male Antifertility Agents. Gossypol --
a new antifertility
agent for males. Chin
Med J (New series) 1978; 58, 455-60. Correspondence
to: Prof.
Zhi-Ping GU, Shanghai Institute of Materia Medica, Chinese Academy of
Sciences, 294 Taiyuan Road, Shanghai 200031, China.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||